Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment
Authors:
Open Access
- 26 December 2024
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 1-10
Abstract
Purpose The blood concentrations of some tyrosine kinase inhibitors are known to decrease with long-term administration. We evaluated the variability in the serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment. Methods This study prospectively recruited patients who received sunitinib for metastatic renal cell carcinoma at the Showa University Hospital between March 2020 and January 2022. Bivariate correlations between the serum concentration/dose (C/D) ratios of sunitinib and its metabolites (i.e., N-desethyl sunitinib and sunitinib N-oxide) and treatment duration were evaluated using Pearson’s correlation coefficient. Results Seven patients were enrolled, and 79 blood samples were collected. Among six patients who received sunitinib for > 1 year, three showed a decreasing trend in the C/D ratio of sunitinib (Pt1: r = -0.608, p = 0.047; Pt2: r = -0.555, p = 0.077; Pt6: r = -0.590, p = 0.073). In these patients, the median annual decrease in the C/D ratio of sunitinib was 55.8% (26.5–63.2%). Additionally, two of the three patients also showed a decrease in the C/D ratio of N-desethyl sunitinib. The ratio of N-desethyl sunitinib/sunitinib concentration at baseline and the end of follow-up was similar between the C/D-decreased and C/D-non-decreased groups. Conclusion This study showed that the C/D ratio of sunitinib decreased by half over time in half of the patients who received long-term sunitinib treatment despite continuing the same dose. Therefore, serum concentrations of sunitinib and its metabolites should be monitored periodically in patients receiving long-term treatment to prevent decrease in serum sunitinib concentrations.Keywords
This publication has 31 references indexed in Scilit:
- Therapeutic drug monitoring of oral targeted antineoplastic drugsEuropean Journal of Clinical Pharmacology, 2020
- Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinomaInternational Journal of Clinical Oncology, 2018
- Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in OncologyClinical Pharmacology & Therapeutics, 2017
- Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoringCancer Chemotherapy and Pharmacology, 2017
- Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment OptionsClinical Pharmacokinetics, 2017
- Exposure–Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular CarcinomaClinical Pharmacokinetics, 2013
- Sorafenib exposure decreases over time in patients with hepatocellular carcinomaInvestigational New Drugs, 2011
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysisCancer Chemotherapy and Pharmacology, 2009
- Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma GroupCancer Chemotherapy and Pharmacology, 2004
- Altered gastric emptying and secretion in primary anorexia nervosaGastroenterology, 1979